Obsidian Therapeutics (OBX)

Market Price (8/8/2026): $27.0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

Obsidian Therapeutics (OBX)

Market Price (8/8/2026): $27.0
Market Cap: $-
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies.

Weak multi-year price returns
2Y Excs Rtn is -64%, 3Y Excs Rtn is -91%

High stock price volatility
Vol 12M is 133%

0	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies.
1	Weak multi-year price returns 2Y Excs Rtn is -64%, 3Y Excs Rtn is -91%
2	High stock price volatility Vol 12M is 133%

Valuation & Metrics

	8/8/26	2025	2024
Share Price	$27.00	�	�
Mkt Cap ($ Mil)	0.0	-	-
+ Debt ($ Mil)	3.6	0.0	0.0
- Cash ($ Mil)	58.8	0.0	0.0
TEV ($ Mil)	-55.2
Valuation Ratios
P/S	-	-	-
P/EBIT	-	-	-
P/E	-	-	-
P/FCF	-	-	-
Sector Ratios (* = sector average)
P/S *	4.2	4.3	4.1
P/EBIT *	-1.8	-1.6	-1.5
P/E *	-1.8	-1.7	-1.6
P/FCF *	-1.8	-1.7	-1.5

	8/8/26	2025	2024
Share Price	$27.00	�	�
Mkt Cap ($ Mil)	0.0	-	-
+ Debt ($ Mil)	3.6	0.0	0.0
- Cash ($ Mil)	58.8	0.0	0.0
TEV ($ Mil)	-55.2
Valuation Ratios
P/S	-	-	-
P/EBIT	-	-	-
P/E	-	-	-
P/FCF	-	-	-
Sector Ratios (* = sector average)
P/S *	4.2	4.3	4.1
P/EBIT *	-1.8	-1.6	-1.5
P/E *	-1.8	-1.7	-1.6
P/FCF *	-1.8	-1.7	-1.5

null

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Granted Patents	8	8052026	Link
Number of Active Clinical Trials	2	12122023	Link
Lead Program Clinical Phase	Phase 2	4212026	Link
Total Number of Employees	105	4302026	Link

Price Chart

null

No Events

Why The Stock Moved

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

4/30/2026 to 8/7/2026

	Return	Correlation
OBX
Market (SPY)	7.6%	40.9%
Sector (XLV)	13.5%	-92.0%

Fundamental Drivers

null
null

Market Drivers

1/31/2026 to 8/7/2026

	Return	Correlation
OBX
Market (SPY)	12.1%	40.9%
Sector (XLV)	7.5%	-92.0%

Fundamental Drivers

null
null

Market Drivers

7/31/2025 to 8/7/2026

	Return	Correlation
OBX
Market (SPY)	23.4%	40.9%
Sector (XLV)	28.7%	-92.0%

Fundamental Drivers

null
null

Market Drivers

7/31/2023 to 8/7/2026

	Return	Correlation
OBX
Market (SPY)	74.9%	40.9%
Sector (XLV)	29.3%	-92.0%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
OBX Return	-	-	-	-	-	-17%	-17%
Peers Return	-36%	-63%	-32%	-36%	16%	13%	-87%
S&P 500 Return	27%	-19%	24%	23%	16%	13%	105%
Monthly Win Rates [3]
OBX Win Rate	-	-	-	-	-	0%
Peers Win Rate	31%	30%	35%	37%	47%	40%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
OBX Max Drawdown	-	-	-	-	-	-
Peers Max Drawdown	-59%	-71%	-70%	-73%	-65%	-53%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: IOVA, LYEL, ALLO, CRBU, ATRA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)

OBX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2025 US Tariff Shock
% Loss	-11.7%	-18.8%
% Gain to Breakeven	13.3%	23.1%
Time to Breakeven	142 days	79 days
2022 Inflation Shock & Fed Tightening
% Loss	-13.8%	-24.5%
% Gain to Breakeven	15.9%	32.4%
Time to Breakeven	166 days	427 days
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-15.0%	-19.2%
% Gain to Breakeven	17.6%	23.8%
Time to Breakeven	191 days	105 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-15.9%	-12.2%
% Gain to Breakeven	18.9%	13.9%
Time to Breakeven	165 days	62 days
2011 US Debt Ceiling Crisis & European Contagion
% Loss	-15.8%	-17.9%
% Gain to Breakeven	18.8%	21.8%
Time to Breakeven	153 days	123 days

Compare to IOVA, LYEL, ALLO, CRBU, ATRA

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

OBX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
2008-2009 Global Financial Crisis
% Loss	-37.9%	-53.4%
% Gain to Breakeven	61.1%	114.4%
Time to Breakeven	767 days	1085 days

Compare to IOVA, LYEL, ALLO, CRBU, ATRA

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Obsidian Therapeutics (OBX)

Business Description

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

Interactive Breakdown

null

null

Better Bets vs. Obsidian Therapeutics (OBX)

null

Latest Trefis Analyses

null

Trade Ideas

Select ideas related to OBX.

null

Recent Active Movers

Top Gainers

Ticker	Company	Category	1D Rtn	YTD Rtn
RING	iShares MSCI Global Gold Miners ETF	Equity	7.8%	5.9%
NASA	Tema Space Innovators ETF	Equity	5.8%	1.5%
ARKK	ARK Innovation ETF	Equity	4.9%	3.3%
XOVR	EntrepreneurShares Series Trust ERSha...	Equity	4.5%	-0.0%
URA	Global X Uranium ETF	Equity	4.0%	5.1%
ARKX	ARK Space & Defense Innovation ETF	Equity	3.8%	-1.8%
ARKQ	ARK Autonomous Technology & Robotics ETF	Equity	3.8%	11.5%
IGV	iShares Expanded Tech-Software Sector...	Equity	3.3%	-2.8%
ARKW	ARK Next Generation Internet ETF	Equity	3.1%	0.1%
SLV	iShares Silver Trust	Commodity	3.0%	-10.7%

Top Losers

Ticker	Company	Category	1D Rtn	YTD Rtn
EWZ	iShares MSCI Brazil ETF	Equity	-1.3%	11.2%
XLE	State Street Energy Select Sector SPD...	Equity	-1.1%	29.4%
ILF	iShares Latin America 40 ETF	Equity	-0.8%	13.7%
USO	United States Oil Fund LP	Commodity	-0.7%	70.6%
FXN	First Trust Energy AlphaDEX Fund	Equity	-0.5%	30.7%
XOP	State Street SPDR S&P Oil & Gas Explo...	Equity	-0.4%	32.3%
KRE	State Street SPDR S&P Regional Bankin...	Equity	-0.4%	18.3%
XLF	State Street Financial Select Sector ...	Equity	-0.4%	5.7%
IYJ	iShares U.S. Industrials ETF	Equity	-0.1%	13.8%
JEPI	JPMorgan Equity Premium Income ETF	Equity	-0.0%	4.8%

Top Gainers

Ticker	Company	Category	1W Rtn	YTD Rtn
RING	iShares MSCI Global Gold Miners ETF	Equity	22.3%	5.9%
NASA	Tema Space Innovators ETF	Equity	18.2%	1.5%
URA	Global X Uranium ETF	Equity	14.9%	5.1%
ARKX	ARK Space & Defense Innovation ETF	Equity	12.0%	-1.8%
ARKK	ARK Innovation ETF	Equity	11.5%	3.3%
ARKQ	ARK Autonomous Technology & Robotics ETF	Equity	11.1%	11.5%
GDE	WisdomTree Efficient Gold Plus Equity...	Equity	10.2%	-4.3%
SLV	iShares Silver Trust	Commodity	9.8%	-10.7%
MISL	First Trust Indxx Aerospace & Defense...	Equity	9.7%	10.4%
SOXQ	Invesco PHLX Semiconductor ETF	Equity	9.2%	74.5%

Top Losers

Ticker	Company	Category	1W Rtn	YTD Rtn
USO	United States Oil Fund LP	Commodity	-8.7%	70.6%
XOP	State Street SPDR S&P Oil & Gas Explo...	Equity	-6.2%	32.3%
EWZ	iShares MSCI Brazil ETF	Equity	-3.6%	11.2%
XLE	State Street Energy Select Sector SPD...	Equity	-3.4%	29.4%
UNG	United States Natural Gas Fund LP	Commodity	-3.2%	-20.6%
FXN	First Trust Energy AlphaDEX Fund	Equity	-3.0%	30.7%
ILF	iShares Latin America 40 ETF	Equity	-2.1%	13.7%
DBC	Invesco DB Commodity Index Tracking Fund	Commodity	-1.8%	29.3%
PDBC	Invesco Optimum Yield Diversified Com...	Commodity	-1.8%	30.2%
XLU	State Street Utilities Select Sector ...	Equity	-1.7%	2.9%

Top Gainers

Ticker	Company	Category	1M Rtn	YTD Rtn
RING	iShares MSCI Global Gold Miners ETF	Equity	19.8%	5.9%
PALL	ETFS Physical Palladium Shares	Commodity	10.4%	-13.8%
ETHA	iShares Ethereum Trust ETF	Cryptocurrency	9.7%	-35.5%
IGV	iShares Expanded Tech-Software Sector...	Equity	9.4%	-2.8%
PPLT	ETFS Physical Platinum Shares	Commodity	8.4%	-15.0%
COWZ	Pacer US Cash Cows 100 ETF	Equity	8.3%	15.4%
FXI	iShares China Large-Cap ETF	Equity	8.3%	-5.5%
KWEB	KraneShares CSI China Internet ETF	Equity	8.2%	-15.8%
USO	United States Oil Fund LP	Commodity	8.2%	70.6%
AKRE	Akre Focus ETF	Equity	7.5%	-10.1%

Top Losers

Ticker	Company	Category	1M Rtn	YTD Rtn
EWY	iShares MSCI South Korea ETF	Equity	-10.1%	70.8%
UNG	United States Natural Gas Fund LP	Commodity	-10.1%	-20.6%
SOXX	iShares Semiconductor ETF	Equity	-6.6%	80.5%
ICLN	iShares Global Clean Energy ETF	Equity	-5.3%	11.4%
SOXQ	Invesco PHLX Semiconductor ETF	Equity	-4.7%	74.5%
XOVR	EntrepreneurShares Series Trust ERSha...	Equity	-4.5%	-0.0%
NASA	Tema Space Innovators ETF	Equity	-4.3%	1.5%
XBI	State Street SPDR S&P Biotech ETF	Equity	-4.2%	29.1%
SMH	VanEck Semiconductor ETF	Equity	-4.1%	61.8%
MTUM	iShares MSCI USA Momentum Factor ETF	Equity	-3.7%	23.7%

Peer Comparisons

Peers to compare with:

Financials

	OBX	IOVA	LYEL	ALLO	CRBU	ATRA	Median
Name	Obsidian.	Iovance .	Lyell Im.	Allogene.	Caribou .	Atara Bi.
Mkt Price	27.50	6.34	14.71	2.01	1.65	8.45	7.39
Mkt Cap	-	2.9	0.3	0.5	0.2	0.1	0.3
Rev LTM	-	325	0	0	11	23	11
Op Inc LTM	-	-296	-190	-188	-120	-6	-188
FCF LTM	-	-296	-134	-110	-102	-26	-110
FCF 3Y Avg	-	-340	-155	-178	-120	-93	-155
CFO LTM	-	-264	-133	-109	-101	-26	-109
CFO 3Y Avg	-	-319	-154	-178	-114	-92	-154

Growth & Margins

	OBX	IOVA	LYEL	ALLO	CRBU	ATRA	Median
Name	Obsidian.	Iovance .	Lyell Im.	Allogene.	Caribou .	Atara Bi.
Rev Chg LTM	-	34.5%	-55.0%	-	13.0%	-88.4%	-21.0%
Rev Chg 3Y Avg	-	4,780.4%	-47.9%	-	23.4%	115.8%	69.6%
Rev Chg Q	-	65.7%	-50.0%	-	1.9%	-99.5%	-24.1%
QoQ Delta Rev Chg LTM	-	13.8%	-12.9%	-	0.4%	-80.8%	-6.3%
Op Inc Chg LTM	-	27.9%	12.1%	25.8%	26.9%	57.2%	26.9%
Op Inc Chg 3Y Avg	-	10.4%	2.9%	18.9%	-3.4%	54.9%	10.4%
Op Mgn LTM	-	-91.1%	-704,307.4%	-	-1,067.2%	-24.8%	-579.2%
Op Mgn 3Y Avg	-	-554.2%	-494,189.8%	-	-1,036.0%	-233.6%	-795.1%
QoQ Delta Op Mgn LTM	-	34.2%	-96,168.7%	-	153.3%	-54.9%	-10.4%
CFO/Rev LTM	-	-81.3%	-493,555.6%	-	-903.8%	-111.8%	-507.8%
CFO/Rev 3Y Avg	-	-464.4%	-357,582.1%	-	-866.5%	-225.4%	-665.4%
FCF/Rev LTM	-	-91.2%	-496,188.9%	-	-909.2%	-111.8%	-510.5%
FCF/Rev 3Y Avg	-	-482.4%	-359,105.7%	-	-896.2%	-226.3%	-689.3%

Valuation

	OBX	IOVA	LYEL	ALLO	CRBU	ATRA	Median
Name	Obsidian.	Iovance .	Lyell Im.	Allogene.	Caribou .	Atara Bi.
Mkt Cap	-	2.9	0.3	0.5	0.2	0.1	0.3
P/S	-	8.8	12,729.1	-	14.1	5.1	11.5
P/Op Inc	-	-9.6	-1.8	-2.6	-1.3	-20.8	-2.6
P/EBIT	-	-9.6	-1.8	-2.8	-1.3	-20.4	-2.8
P/E	-	-9.9	-1.4	-2.8	-1.2	-12.6	-2.8
P/CFO	-	-10.8	-2.6	-4.4	-1.6	-4.6	-4.4
Total Yield	-	-10.1%	-72.3%	-36.0%	-84.2%	-8.0%	-36.0%
Dividend Yield	-	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-	-29.9%	-71.8%	-53.7%	-86.9%	-161.5%	-71.8%
D/E	-	0.0	0.1	0.2	0.2	0.1	0.1
Net D/E	-	-0.0	-0.5	-0.4	-0.6	0.0	-0.4

Returns

	OBX	IOVA	LYEL	ALLO	CRBU	ATRA	Median
Name	Obsidian.	Iovance .	Lyell Im.	Allogene.	Caribou .	Atara Bi.
1M Rtn	-19.1%	48.1%	-4.5%	-5.2%	-14.9%	-12.4%	-8.8%
3M Rtn	-19.1%	75.1%	-23.9%	-11.8%	-14.9%	1.3%	-13.4%
6M Rtn	-19.1%	150.6%	-35.2%	18.9%	5.1%	73.2%	12.0%
12M Rtn	-19.1%	140.2%	29.9%	91.4%	-8.8%	-22.9%	10.6%
3Y Rtn	-19.1%	-11.2%	-69.4%	-54.9%	-74.8%	-85.1%	-62.1%
1M Excs Rtn	-22.0%	42.2%	-6.1%	-7.1%	-17.8%	-17.9%	-12.5%
3M Excs Rtn	-24.8%	72.9%	-32.4%	-17.2%	-18.0%	-20.6%	-19.3%
6M Excs Rtn	-33.2%	154.5%	-49.1%	9.2%	-2.6%	73.3%	3.3%
12M Excs Rtn	-41.4%	123.5%	10.5%	67.4%	-34.5%	-48.0%	-12.0%
3Y Excs Rtn	-91.0%	-83.6%	-144.0%	-129.0%	-148.5%	-155.8%	-136.5%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024
Period End	3/31/2026	12/31/2025	12/31/2024
Filing Date	7/2/2026	7/2/2026	7/2/2026
Key Financials
Total Revenue	-	0	0
Gross Profit	-	-	-
EBITDA	-	-104	-90
Operating Income	-	-106	-91
Net Income	-	-101	-83
EPS	-	-	-
Growth Rates
Total Revenue Growth	-	-	-
EBITDA Growth	-	-16.1%	-
Operating Income Growth	-	-15.8%	-
Net Income Growth	-	-21.1%	-
Margins
Gross Margin	-	-	-
EBITDA Margin	-	-	-
Operating Income Margin	-	-	-
Net Income Margin	-	-	-
Cash & Debt
Total Cash	59	80	168
Total Debt	4	4	7
Net Debt / (Cash)	-55	-76	-161
Cash Flows & CapEx
Net Cash from Operations	-	-90	-75
Total CapEx	-0	-0	-1
Free Cash from Operations	-	-90	-76
Returns to Shareholders
Dividends	0	-0	-0
Share Repurchases	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1
Period End	3/31/2026
Filing Date	7/2/2026
Key Financials Quarterly
Total Revenue	0
Ebitda	-20
Operating Income	-20
Net Income	-20
EPS	�
Key Financials TTM
Total Revenue TTM	-
Ebitda TTM	-
Operating Income TTM	-
Net Income TTM	-
Growth Rates Quarterly
Total Revenue Growth	-
EBITDA Growth	-
Operating Income Growth	-
Net Income Growth	-
Margins Quarterly
EBITDA Margin	-
Operating Income Margin	-
Net Income Margin	-
Cash & Debt
Total Cash	59
Total Debt	4
Net Debt / (Cash)	-55
Cash Flows Quarterly
FCF from Operations	-22
Cash Flows TTM
FCF from Operations TTM	-
Returns to Shareholders Quarterly
Dividends	0
Share Repurchases	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-

Segment Financials

Revenue by Segment

$ Mil	2025	2024
Developing engineered cell and gene therapies to deliver transformative outcomes for patients	0	0
Total	0	0

Net Income by Segment

$ Mil	2025	2024
Developing engineered cell and gene therapies to deliver transformative outcomes for patients	-101	-83
Total	-101	-83

Price Behavior

null

OBX Betas & Captures as of 7/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta
Up Beta	�	�	�	�	�	�
Down Beta	�	�	�	�	�	�
Up Capture	0%	0%	0%	0%	0%	0%
Bmk +ve Days	11	22	35	67	138	427
Stock +ve Days
Down Capture	-0%	-0%	-0%	-0%	-0%	-0%
Bmk -ve Days	11	21	28	59	114	326
Stock -ve Days

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with OBX
OBX	-19.2%	133.1%	-12.47	-
Sector ETF (XLV)	28.7%	15.5%	1.42	-92.0%
Equity (SPY)	23.3%	12.8%	1.36	40.9%
Gold (GLD)	28.5%	28.4%	0.87	-90.9%
Commodities (DBC)	32.9%	19.8%	1.32	29.3%
Real Estate (VNQ)	14.2%	13.8%	0.72	-35.5%
Bitcoin (BTCUSD)	-44.2%	42.9%	-1.23	-95.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with OBX
OBX	-4.2%	133.1%	-12.47	-
Sector ETF (XLV)	6.2%	15.0%	0.23	-92.0%
Equity (SPY)	13.5%	17.2%	0.61	40.9%
Gold (GLD)	18.6%	18.6%	0.81	-90.9%
Commodities (DBC)	8.2%	19.6%	0.31	29.3%
Real Estate (VNQ)	2.3%	18.9%	0.02	-35.5%
Bitcoin (BTCUSD)	8.8%	53.0%	0.35	-95.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with OBX
OBX	-2.1%	133.1%	-12.47	-
Sector ETF (XLV)	10.1%	16.6%	0.49	-92.0%
Equity (SPY)	15.4%	17.9%	0.73	40.9%
Gold (GLD)	12.1%	16.2%	0.61	-90.9%
Commodities (DBC)	7.4%	18.0%	0.33	29.3%
Real Estate (VNQ)	4.8%	20.7%	0.20	-35.5%
Bitcoin (BTCUSD)	58.2%	66.2%	0.98	-95.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Returns Analyses

null

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	07/02/2026	424B3

Recent Forward Guidance

Updated 8/4/2026

Latest: null Earnings Reported 8/3/2026

null

Insider Activity

Updated null

Expand for Morenull

Investor Activity (13F)

Updated

13F holdings as of

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 8/7/2026

Obsidian Therapeutics (OBX)

Market Price (8/8/2026): $27.0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

Obsidian Therapeutics (OBX)

Market Price (8/8/2026): $27.0Market Cap: $-Sector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Obsidian Therapeutics (OBX)

Interactive Breakdown

Better Bets vs. Obsidian Therapeutics (OBX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

Investor Activity (13F)

OBX Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

Diversification Alternatives

Market Price (8/8/2026): $27.0
Market Cap: $-
Sector: Health Care
Industry: Biotechnology